Galapagos NV (NASDAQ:GLPG) has received an average recommendation of “Buy” from the eleven ratings firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $101.50.
Several research firms have weighed in on GLPG. Stifel Nicolaus upgraded shares of Galapagos NV from a “hold” rating to a “buy” rating and increased their price target for the stock from $83.00 to $101.00 in a research report on Friday, August 11th. Zacks Investment Research upgraded shares of Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research report on Friday, July 14th. TheStreet upgraded shares of Galapagos NV from a “d+” rating to a “c” rating in a research report on Wednesday, May 17th. BTIG Research reiterated a “buy” rating and issued a $98.00 price target on shares of Galapagos NV in a research report on Tuesday, June 20th. Finally, BidaskClub upgraded shares of Galapagos NV from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC purchased a new stake in shares of Galapagos NV in the first quarter worth $161,000. Acadian Asset Management LLC purchased a new stake in shares of Galapagos NV in the second quarter worth $166,000. New York State Common Retirement Fund purchased a new stake in shares of Galapagos NV in the second quarter worth $166,000. Bank of Montreal Can increased its stake in shares of Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 1,922 shares in the last quarter. Finally, Pacad Investment Ltd. purchased a new stake in shares of Galapagos NV in the second quarter worth $168,000. 23.63% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.thestockobserver.com/2017/09/12/galapagos-nv-glpg-given-consensus-recommendation-of-buy-by-analysts.html.
Shares of Galapagos NV (NASDAQ GLPG) traded down 0.30% during mid-day trading on Tuesday, hitting $100.56. The stock had a trading volume of 116,747 shares. The stock’s market cap is $5.12 billion. The firm’s 50-day moving average price is $85.67 and its 200 day moving average price is $82.58. Galapagos NV has a 12-month low of $53.93 and a 12-month high of $100.75.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.